These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38429661)

  • 1. Serotonin as a biomarker of toxin-induced Parkinsonism.
    Buchanan AM; Mena S; Choukari I; Vasa A; Crawford JN; Fadel J; Maxwell N; Reagan L; Cruikshank A; Best J; Nijhout HF; Reed M; Hashemi P
    Mol Med; 2024 Mar; 30(1):33. PubMed ID: 38429661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Fidalgo C; Ko WK; Tronci E; Li Q; Stancampiano R; Chuan Q; Bezard E; Carta M
    Neuroscience; 2015 Jul; 298():389-96. PubMed ID: 25907446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Johnston TH; Geva M; Steiner L; Orbach A; Papapetropoulos S; Savola JM; Reynolds IJ; Ravenscroft P; Hill M; Fox SH; Brotchie JM; Laufer R; Hayden MR
    Mov Disord; 2019 May; 34(5):708-716. PubMed ID: 30575996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C
    Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
    Iravani MM; Jackson MJ; Kuoppamäki M; Smith LA; Jenner P
    J Neurosci; 2003 Oct; 23(27):9107-15. PubMed ID: 14534244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
    Huot P; Johnston TH; Lewis KD; Koprich JB; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
    Neuropharmacology; 2014 Jul; 82():76-87. PubMed ID: 24447715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update.
    Corsi S; Stancampiano R; Carta M
    Prog Brain Res; 2021; 261():287-302. PubMed ID: 33785132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mGluR
    Kang W; Nuara SG; Bédard D; Frouni I; Kwan C; Hamadjida A; Gourdon JC; Gaudette F; Beaudry F; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2347-2355. PubMed ID: 37410156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
    Koprich JB; Huot P; Fox SH; Jarvie K; Lang AE; Seeman P; Brotchie JM
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():151-6. PubMed ID: 23306217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.